pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Galafold
drug
save

migalastat hydrochloride

Marketedupdated 3mo ago
by $FOLD AMICUS THERAPEUTICS, INC.
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
May 16, 2027
274 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (62)

  • Jan 11, 2042method-of-use (U-2371)US 11833164
  • Mar 25, 2039method-of-use (U-2371)US 11633388
  • Mar 17, 2039compositionUS 11622962
  • Feb 20, 2039method-of-use (U-2371)US 11642334
  • Feb 16, 2039compositionUS 11826360
  • Feb 6, 2039method-of-use (U-2371)US 11357784
  • Aug 17, 2038compositionUS 11903938
  • May 30, 2038method-of-use (U-2371)US 10251873
  • May 30, 2038method-of-use (U-2371)US 10471053
  • May 30, 2038method-of-use (U-2371)US 10792278
  • May 30, 2038method-of-use (U-2371)US 10792279
  • May 30, 2038method-of-use (U-2371)US 10799491
  • May 30, 2038method-of-use (U-2371)US 10806727
  • May 30, 2038method-of-use (U-2371)US 10849889
  • May 30, 2038method-of-use (U-2371)US 10849890
  • May 30, 2038method-of-use (U-2371)US 10857141
  • May 30, 2038method-of-use (U-2371)US 10857142
  • May 30, 2038method-of-use (U-2371)US 10874655
  • May 30, 2038method-of-use (U-2371)US 10874656
  • May 30, 2038method-of-use (U-2371)US 10874657
  • May 30, 2038method-of-use (U-2371)US 11278536
  • May 30, 2038method-of-use (U-2371)US 11278537
  • May 30, 2038method-of-use (U-2371)US 11278538
  • May 30, 2038method-of-use (U-2371)US 11278539
  • May 30, 2038method-of-use (U-2371)US 11278540
  • May 30, 2038compositionUS 11304940
  • May 30, 2038method-of-use (U-2371)US 11357761
  • May 30, 2038method-of-use (U-2371)US 11357762
  • May 30, 2038method-of-use (U-2371)US 11357763
  • May 30, 2038compositionUS 11357764
  • May 30, 2038compositionUS 11357765
  • May 30, 2038compositionUS 11376244
  • May 30, 2038method-of-use (U-2371)US 11389436
  • May 30, 2038method-of-use (U-2371)US 11389437
  • May 30, 2038compositionUS 11426396
  • May 30, 2038method-of-use (U-2371)US 11458128
  • May 30, 2038compositionUS 11612593
  • May 30, 2038compositionUS 11612594
  • May 30, 2038compositionUS 11633387
  • May 30, 2038method-of-use (U-2371)US 11666564
  • May 30, 2038compositionUS 11786516
  • May 30, 2038method-of-use (U-2371)US 11813255
  • May 30, 2038compositionUS 12042488
  • May 30, 2038compositionUS 12042489
  • May 30, 2038method-of-use (U-2371)US 12042490
  • May 30, 2038compositionUS 12109205
  • May 30, 2038compositionUS 12280042
  • Mar 15, 2037method-of-use (U-2371)US 10076514
  • Mar 15, 2037method-of-use (U-2371)US 11234972
  • Oct 20, 2031method-of-use (U-2371)US RE48608
  • Feb 12, 2029method-of-use (U-2371)US 108139212.5y
  • Feb 12, 2029method-of-use (U-2371)US 90955842.5y
  • Apr 28, 2028method-of-use (U-2371)US 105250451.7y
  • Apr 28, 2028method-of-use (U-2371)US 109258661.7y
  • Apr 28, 2028method-of-use (U-2371)US 110335381.7y
  • Apr 28, 2028method-of-use (U-2372)US 99996181.7y
  • May 16, 2027method-of-use (U-2371)US 10383864274d
  • May 16, 2027method-of-use (U-2371)US 10406143274d
  • May 16, 2027method-of-use (U-2371)US 11241422274d
  • May 16, 2027method-of-use (U-2371)US 9000011274d
  • May 16, 2027method-of-use (U-2371)US 9480682274d
  • May 16, 2027method-of-use (U-2371)US 9987263274d

News(0)

no news has mentioned this drug yet

brand
Galafold
generic
migalastat hydrochloride
indication
Fabry Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?